Literature DB >> 9034752

Coronary endothelial function in health and disease.

J C Burnett1.   

Abstract

The endothelium participates in the control of coronary vascular tone and growth through the release of vasodilating and growth-inhibiting factors such as nitric oxide (NO) and C-type natriuretic peptide (CNP), and vasoconstricting and growth-promoting substances such as endothelin-1 (ET-1). Abnormalities in NO and/or CNP generation or actions have been demonstrated in various cardiovascular pathophysiological states, specifically atherosclerosis, congestive heart failure, hypertension and hypercholesterolaemia. Moreover, an increase in plasma ET-1 levels has also been reported in these disease states. When these observations are considered together, these states may be characterised by an attenuated release or action of NO and/or CNP, together with an augmented release of ET-1. Thus, an imbalance between these opposing factors may contribute to the alteration in vascular tone and the vascular remodelling characteristics of cardiovascular disease. The following article summarises the present knowledge of endothelial control of the coronary circulation and derangements associated with coronary endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9034752     DOI: 10.2165/00003495-199700531-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  41 in total

Review 1.  Nitric oxide and endothelins: novel autocrine/paracrine regulators of the circulation.

Authors:  P A Marsden; B M Brenner
Journal:  Semin Nephrol       Date:  1991-03       Impact factor: 5.299

2.  Integrated cardiac, renal, and endocrine actions of endothelin.

Authors:  W L Miller; M M Redfield; J C Burnett
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

3.  Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults.

Authors:  P Clarkson; M R Adams; A J Powe; A E Donald; R McCredie; J Robinson; S N McCarthy; A Keech; D S Celermajer; J E Deanfield
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

4.  Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells.

Authors:  C M Wei; S Hu; V M Miller; J C Burnett
Journal:  Biochem Biophys Res Commun       Date:  1994-11-30       Impact factor: 3.575

5.  C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems.

Authors:  R S Wright; C M Wei; C H Kim; M Kinoshita; Y Matsuda; L L Aarhus; J C Burnett; W L Miller
Journal:  J Am Coll Cardiol       Date:  1996-10       Impact factor: 24.094

6.  Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia.

Authors:  A M Zeiher; T Krause; V Schächinger; J Minners; E Moser
Journal:  Circulation       Date:  1995-05-01       Impact factor: 29.690

7.  Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans.

Authors:  A Lerman; D R Holmes; M R Bell; K N Garratt; R A Nishimura; J C Burnett
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

8.  Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor.

Authors:  C R Cannan; J C Burnett; R R Brandt; A Lerman
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

9.  Cardiovascular and renal actions of C-type natriuretic peptide.

Authors:  A J Stingo; A L Clavell; L L Aarhus; J C Burnett
Journal:  Am J Physiol       Date:  1992-01

10.  Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat.

Authors:  T F Lüscher; P M Vanhoutte
Journal:  Hypertension       Date:  1986-04       Impact factor: 10.190

View more
  1 in total

Review 1.  Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.

Authors:  K L Goa; M Haria; M I Wilde
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.